Currently, the Centers for Medicare and Medicaid Services (CMS) does not allow pharmacists to bill Medicare directly for patient-specific TDD therapies.
Current CMS policy limits patient and physician choice. This class of medications, which are individually compounded for each patient, can be expensive, leaving physicians and patients at real financial risk under the current CMS policy. The result: Patients across the country have limited access to this important alternative to oral opioids.
Tell your Congressional representatives why it’s important for CMS to return to direct pharmacy billing for TDD therapies. Complete the form letter below.